Verde, Z <br/><br/>
Are serotonergic system genes associated to smoking cessation therapy success in addition to CYP2A6?  [electronic resource] 

 -  Pharmacopsychiatry  Jan 2014 
 - 33-6 p.  digital 
<br/><br/> Publication Type: Letter; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1439-0795 
<br/><br/><label>Standard No.: </label>10.1055/s-0033-1358393  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aryl Hydrocarbon Hydroxylases--genetics<br/>Bupropion--therapeutic use<br/>Cytochrome P-450 CYP2A6<br/>Dopamine Uptake Inhibitors--therapeutic use<br/>Female<br/>Genetic Association Studies<br/>Genotype<br/>Humans<br/>Male<br/>Middle Aged<br/>Nicotine--therapeutic use<br/>Nicotinic Agonists--therapeutic use<br/>Pharmacogenetics<br/>Polymorphism, Genetic--genetics<br/>Receptor, Serotonin, 5-HT2A--genetics<br/>Serotonin Plasma Membrane Transport Proteins--genetics<br/>Smoking Cessation<br/>Tobacco Use Disorder--genetics